DSR Biomaterials

Surface modification and biomaterials consultancy for healthcare, diagnostics and materials science companies

Bromley, United KingdomFounded 2020dsrbiomaterials.comWebsite technologies

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-11-13

About DSR Biomaterials

DSR Biomaterials provides strategic and technical consultancy on surface modification, coatings and biomaterials development. Services include product development, testing and validation, scale-up, manufacturing and contract research.

It supports organisations in healthcare, diagnostics and materials science through research, development and commercialisation, including coating strategies, biocompatibility, drug delivery and quality compliance. The company is registered in Bromley, United Kingdom, and was founded in 2020.

Product: Consultancy and strategic support for surface modification, coating technologies and biomaterials development.

Jobs at DSR Biomaterials

No open positions listed right now.

More biotech & pharma companies

  • Duke Street Bio

    Develops cancer therapies targeting DNA damage repair deficiencies for patients with cancer
    London, United KingdomBiotech & pharmaFounded 2020
  • E.V.A Biosystems

    Biological additives for plastic manufacturers to make conventional plastics selectively degradable in target environments
    Edinburgh, United KingdomBiotech & pharmaFounded 2021
    New on Evolc
  • Earlham Enterprises

    Contract research and genomics services for academic, public-sector, nonprofit and private organisations
    Norwich, United KingdomBiotech & pharmaFounded 2009
  • Eco Animal Health

    Veterinary medicines and vaccines for pig, poultry and cattle producers, sold directly and through distributors in over 70 countries
    London, United KingdomBiotech & pharmaFounded 1991
    New on Evolc
  • Ecotype Genetics

    DNA testing and species identification services for ecologists, conservation groups and environmental researchers in the UK
    Hove, United KingdomBiotech & pharmaFounded 2018
    New on Evolc
  • Elasmogen

    Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patients
    Foresterhill, United KingdomBiotech & pharmaFounded 2014

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Analytics

  • Google Analytics 4High confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.